Hyperglycemia Global Clinical Trials Review, H1, 2014

GlobalData
April 30, 2014
113 Pages - SKU: GBDT5239236
AMPK Beta Inhibitors -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
AMPK Beta Inhibitors -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“AMPK Beta Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for  |  read more...
USD 1,250
Anaplastic Lymphoma Kinase (ALK) Inhibitors -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Anaplastic Lymphoma Kinase (ALK) Inhibitors -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to  |  read more...
USD 1,250
Androgen Antagonists -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Androgen Antagonists -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Androgen Antagonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the  |  read more...
USD 1,250
Angiopoietin Inhibitors -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Angiopoietin Inhibitors -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Angiopoietin Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the  |  read more...
USD 1,250
Angiotensin II Receptor Type 1 (AT1 Receptor) Inhibitors -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Angiotensin II Receptor Type 1 (AT1 Receptor) Inhibitors -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Angiotensin II Receptor Type 1 (AT1 Receptor) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key  |  read more...
USD 1,250
Anti-CD105 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Anti-CD105 Antibody -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Anti-CD105 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the  |  read more...
USD 1,250
Anti-CD22 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Anti-CD22 Antibody -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Anti-CD22 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the  |  read more...
USD 1,250
Anti-CD25 Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Anti-CD25 Antibody -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Anti-CD25 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the  |  read more...
USD 1,250
Anti-CD274 (PD-L1) Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Anti-CD274 (PD-L1) Antibody -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Anti-CD274 (PD-L1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for  |  read more...
USD 1,250
Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014
11/21/2014 | published by: DelveInsight
Anti-CD279 (PD-1) Antibody -Pipeline Insights, 2014 SUMMARY DelveInsight’s,“Anti-CD279 (PD-1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for  |  read more...
USD 1,250
 

SELECT A LICENSE

    Online Download  USD 2,500  
    Site License  USD 5,000  
    Global Site License  USD 7,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!